Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
ConditionAcute Heart Failure
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAntonio Leidi
About this trial
The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes.
The main questions it aims to answer are:
* Does this strategy shorten the length of stay and reduce early hospital readmissions? * Does this strategy improve patients' symptoms and quality of life ?
Researchers will compare LUS to physical examination (PE).
Eligibility criteria
Qualifiers
≥ 18 years old
Planned or actual admission to intermediate care units, general internal medical or cardiology wards
Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis)
Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l).
Disqualifiers
Known isolated right heart failure
Systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg at the moment of inclusion
The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion
Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months
Trial design
Treatments tested in this trial
- LUS decongestive strategy
- PE decongestive strategy
Treatment groups
222 Participants
are divided into 2 treatment groupsSponsors and collaborators
Antonio Leidi
Lead sponsor
University Hospital, Geneva
Sponsor institution
University Hospital, Geneva
Collaborator
Source ClinicalTrials.gov